Genomed

Genomed Forward P/E

The Forward P/E Ratio of Genomed (GEN.WA) as of Oct 20, 2026 is 10.03. In the previous year, Forward P/E Ratio was 30.84 — a change of -67.49% (lower).

Forward P/E

10.03

YoY

-67.49%

Last updated:

Forward P/E Ratio of Genomed is 2025 10.03 . Forward P/E Ratio of Genomed was 2024 30.84 . It decreases by -67.49% lower compared to the previous year.

The Genomed Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
23.04 PLN
Jan 1, 2019
34.03 PLN
Jan 1, 2020
82.68 PLN
Jan 1, 2021
27.54 PLN
Jan 1, 2022
100.87 PLN
Jan 1, 2023
36.80 PLN
Jan 1, 2024
30.84 PLN
Jan 1, 2025
10.03 PLN
The Genomed Forward P/E history
YEARForward P/EYoY
10.03-67.49%
30.84-16.19%
36.80-63.51%
100.87+266.32%
27.54-66.70%
82.68+142.98%
34.03+47.66%
23.04+21.79%
18.92-84.93%
125.56-98.49%
8,314.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomed Stock analysis

What does Genomed do? Genomed SA is a biotechnology company headquartered in Warsaw, Poland, operating within the Health Care sector. The company went public on May 30, 2011, with its ticker listed as GEN.WA and ISIN PLGNOMD00024. Genomed SA specializes in medical diagnostic services, particularly focusing on molecular diagnostics using DNA sequencing technology. The company emphasizes Next Generation Sequencing (NGS) methods for its diagnostic offerings. Its services include analysis of gene mutations linked to over 150 congenital diseases, such as infertility, cancer predisposition, cystic fibrosis, Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy, and obesity. The company aims to integrate genomic technology into personalized medicine and has developed a clinic dedicated to gene treatments. Additionally, Genomed SA provides DNA sequencing, analysis, and synthesis services for research and biotechnology industry clients. The company's website is http://www.genomed.pl/, and it operates primarily in the Mazowieckie region of Poland. Genomed SA's business model centers on leveraging genomic data to improve diagnostic accuracy and support tailored medical interventions. Its focus on NGS technology positions it as a provider of advanced diagnostic solutions within the biotechnology sector. The company's activities reflect a commitment to expanding the application of genomics in clinical settings, particularly for inherited conditions and chronic diseases. Genomed SA's services are designed to assist healthcare providers in making more informed decisions through genetic insights. The firm continues to develop its capabilities in genomic analysis to meet evolving healthcare demands. Genomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomed stock

Forward P/E Ratio of Genomed is 10.03 in 2025.

Forward P/E Ratio of Genomed changed from 30.84 to 10.03, representing a -67.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Genomed since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Genomed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Genomed

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Genomed